A METHODICAL REVIEW ON OMICRON -A NEW VARIANT AS A DRUG DEVELOPER
AbstractIn mid-November 2021, the new OMICRON variety was first discovered in South Africa. As of today, the OMICRON version already appeared on December 15, 2021. Around 77 countries are affected, with the bulk of cases originating in the United States, India, the United Kingdom, and South Africa. OMICRON-positive instances were also reported. The first mortality associated with the novel COVID-19 mutation was reported in the United Kingdom. Recently, a sister variant of OMICRON, 21L or BA.2, has also been discovered. Due to its enormously high number of mutations, viewed enhancement in immune evasion and transmissibility, OMICRON was developed as a new variant of concern (VOC) by the WHO on 26 November 2021. On a global pandemic scale, positive selection of SARS-CoV-2 mutations appears to have begun in late 2020. Since then, the virus has been evolving on two fronts: immune evasion and enhanced transmissibility, as expressed by Delta. This review elaborates the effects of drugs in the management of OMICRON.
Article Information
6
2104-2116
1071 KB
315
English
IJPSR
B. Hemamalini, N. Selvasudha and C. Vinodhini *
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, Tamil Nadu, India.
vinpharma79@gmail.com
18 July 2022
07 April 2023
18 April 2023
10.13040/IJPSR.0975-8232.14(5).2104-16
01 May 2023
Download